NasdaqGS:IONSBiotechs
Ionis Pharmaceuticals (IONS) Stock Valuation After Reassuring Long Term Olezarsen Data
Ionis Pharmaceuticals (IONS) has put fresh clinical data for its triglyceride drug candidate olezarsen in front of investors, with new 24 month results from the CORE OLE study presented at the National Lipid Association Scientific Sessions.
See our latest analysis for Ionis Pharmaceuticals.
The recent olezarsen data come as Ionis shares trade at US$73.28, with the stock down over the year to date but supported by a very large 1 year total shareholder return. This points to strong longer term...